Tandem Diabetes Care Inc (TNDM) - Total Assets
Based on the latest financial reports, Tandem Diabetes Care Inc (TNDM) holds total assets worth $1.15 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Tandem Diabetes Care Inc (TNDM) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Tandem Diabetes Care Inc - Total Assets Trend (2011–2025)
This chart illustrates how Tandem Diabetes Care Inc's total assets have evolved over time, based on quarterly financial data. Explore TNDM long-term investments to assets to see how much of total assets are deployed in long-term investments.
Tandem Diabetes Care Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Tandem Diabetes Care Inc's total assets of $1.15 Billion consist of 70.2% current assets and 29.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 10.3% |
| Accounts Receivable | $165.49 Million | 18.8% |
| Inventory | $128.77 Million | 14.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $11.72 Million | 1.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Tandem Diabetes Care Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see TNDM market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tandem Diabetes Care Inc's current assets represent 70.2% of total assets in 2025, an increase from 70.0% in 2011.
- Cash Position: Cash and equivalents constituted 10.3% of total assets in 2025, down from 61.9% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 18.8% of total assets.
Tandem Diabetes Care Inc Competitors by Total Assets
Key competitors of Tandem Diabetes Care Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥912.83 Million |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$123.37 Million |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Dirui Industrial Co Ltd
SHE:300396
|
China | CN¥2.62 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
Tandem Diabetes Care Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.58 | 2.30 | 6.42 |
| Quick Ratio | 3.07 | 1.81 | 5.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $639.14 Million | $375.26 Million | $589.56 Million |
Tandem Diabetes Care Inc - Advanced Valuation Insights
This section examines the relationship between Tandem Diabetes Care Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.77 |
| Latest Market Cap to Assets Ratio | 1.20 |
| Asset Growth Rate (YoY) | -8.9% |
| Total Assets | $881.11 Million |
| Market Capitalization | $1.06 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Tandem Diabetes Care Inc's assets above their book value (1.20x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Tandem Diabetes Care Inc's assets decreased by 8.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Tandem Diabetes Care Inc (2011–2025)
The table below shows the annual total assets of Tandem Diabetes Care Inc from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $881.11 Million | -8.94% |
| 2024-12-31 | $967.66 Million | +1.57% |
| 2023-12-31 | $952.66 Million | -9.51% |
| 2022-12-31 | $1.05 Billion | +16.31% |
| 2021-12-31 | $905.14 Million | +26.34% |
| 2020-12-31 | $716.41 Million | +119.69% |
| 2019-12-31 | $326.11 Million | +58.08% |
| 2018-12-31 | $206.29 Million | +116.36% |
| 2017-12-31 | $95.35 Million | -15.17% |
| 2016-12-31 | $112.39 Million | -10.17% |
| 2015-12-31 | $125.12 Million | +17.52% |
| 2014-12-31 | $106.46 Million | -34.37% |
| 2013-12-31 | $162.22 Million | +307.40% |
| 2012-12-31 | $39.82 Million | +184.86% |
| 2011-12-31 | $13.98 Million | -- |
About Tandem Diabetes Care Inc
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and … Read more